Aligos Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.0%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$6.58next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 2 B-SUPREME Second Interim Analysis (HBeAg+ Cohort) | 31 Dec 2026 |
| Phase 2a ALG-055009 Topline Data Release (MASH) | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Phase 2 B-SUPREME Trial Enrollment (HBeAg- and HBeAg+ Cohorts) Quarterly114.0
Cash and Short-Term Investments Runway Quarterly54.9MTarget: Sufficient capital to fund operations beyond Q4 2026
Watch Items
- Phase 2 B-SUPREME HBeAg- Cohort Sample Size ExpansionTrigger: Completion of enrollment in the expanded HBeAg- cohort in H2 2026Action: Monitor DSMB recommendations and enrollment pace to ensure statistical powering is optimized for the 2027 topline readout.
- Capital Runway and Financing NeedsTrigger: Cash runway projected to extend only into Q4 2026Action: Evaluate strategic partnership opportunities, licensing deals (similar to the Amoytop agreement), or public/private equity financing to extend the cash runway.
- Phase 2a HERALD Trial of ALG-055009 in MASHTrigger: Release of topline results in H2 2026Action: Assess liver fat reduction (MRI-PDFF) and safety profile compared to competitor THR-β agonists to validate best-in-class potential.
Research as of 19 Jun 2026